Efficacy of convalescent plasma according to blood groups in COVID-19 patients

Hacıbekiroğlu, Tuba; Kalpakci, Yasin; Genç, Ahmed Cihad; Hacıbekiroğlu, İlhan; Sunu, Cenk; Saricaoğlu, Adem; Tomak, Yakup; Karabay, Oğuz; Köroğlu, Mehmet

doi:10.3906/sag-2007-59

Cited by 4 publications

(3 citation statements)

References 22 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study we further compared the clinical outcome between different blood groups and found B blood group patients had a better outcome. This is according to the study conducted by Hacibekiroglu et al [22] who concluded that plasma without anti-A antibody (i.e., except blood group B and O) had lower efficiency when compared with that of plasma containing anti-A antibody (blood group B and O). They further stated that it would be worthwhile to know the titer of anti-A1 antibody in CP with a clear benefit in CP having high anti-A1 antibody titers.…”

Section: Tablementioning

confidence: 58%

Convalescent plasma – An insight into a novel treatment of covid-19 ICU patients

Chowdhry¹,

Hussain²,

Singh³

et al. 2022

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Section: Tablementioning

confidence: 58%

Convalescent plasma – An insight into a novel treatment of covid-19 ICU patients

Chowdhry¹,

Hussain²,

Singh³

et al. 2022

Transfusion and Apheresis Science

View full text Add to dashboard Cite

“…In case of SARS-CoV, the presence of anti-A antibodies, which is a characteristic of groups O and B, inhibits the adhesion of the virus to the ACE2 receptor (Guillon et al, 2008). It is tempting to speculate that this finding may be directly relevant to SARS-CoV-2 as well, given that these findings are consistent with the host response to other viruses such as measles and HIV (Arendrup et al, 1991;Preece et al, 2002) and a trend in increased efficiency of the transfusion of the convalescent plasma from O or B group donors (Hacibekiroğlu et al, 2021).…”

Section: Abo Blood Group and Disease Severitymentioning

confidence: 69%

A Role of Variance in Interferon Genes to Disease Severity in COVID-19 Patients

et al. 2021

View full text Add to dashboard Cite

The rapid rise and global consequences of the novel coronavirus disease 19 (COVID-19) have again brought the focus of the scientific community on the possible host factors involved in patient response and outcome to exposure to the virus. The disease severity remains highly unpredictable, and individuals with none of the aforementioned risk factors may still develop severe COVID-19. It was shown that genotype-related factors like an ABO Blood Group affect COVID-19 severity, and the risk of infection with SARS-CoV-2 was higher for patients with blood type A and lower for patients with blood type O. Currently it is not clear which specific genes are associated with COVID-19 severity. The comparative analysis of COVID-19 and other viral infections allows us to predict that the variants within the interferon pathway genes may serve as markers of the magnitude of immune response to specific pathogens. In particular, various members of Class III interferons (lambda) are reviewed in detail.

show abstract

“…Others have not found viral RNA in the donor some weeks to months among post-infection donors [ 207 ]. ABO compatibility would be prudent [ 208 , 209 ]. In addition, donor samples with high neutralizing capacity would seem to be the best prospects, but not all single measures of antibody will capture seroconverters [ 204 ].…”

Section: Covid-19mentioning

confidence: 99%

Passive Immunity Should and Will Work for COVID-19 for Some Patients

Cimolai¹

2021

CHI

View full text Add to dashboard Cite

In the absence of effective antiviral chemotherapy and still in the context of emerging vaccines for severe acute respiratory syndrome-CoV-2 infections, passive immunotherapy remains a key treatment and possible prevention strategy. What might initially be conceived as a simplified donor-recipient process, the intricacies of donor plasma, IV immunoglobulins, and monoclonal antibody modality applications are becoming more apparent. Key targets of such treatment have largely focused on virus neutralization and the specific viral components of the attachment Spike protein and its constituents (e.g., receptor binding domain, N-terminal domain). The cumulative laboratory and clinical experience suggests that beneficial protective and treatment outcomes are possible. Both a dose-and a time-dependency emerge. Lesser understood are the concepts of bioavailability and distribution. Apart from direct antigen binding from protective immunoglobulins, antibody effector functions have potential roles in outcome. In attempting to mimic the natural but variable response to infection or vaccination, a strong functional polyclonal approach attracts the potential benefits of attacking antigen diversity, high antibody avidity, antibody persistence, and protection against escape viral mutation. The availability and ease of administration for any passive immunotherapy product must be considered in the current climate of need. There is never a perfect product, but yet there is considerable room for improving patient outcomes. Given the variability of human genetics, immunity, and disease, and given the nuances of the virus and its potential for change, passive immunotherapy can be developed that will be effective for some but not all patients. An understanding of such patient variability and limitations is just as important as the understanding of the direct interactions between immunotherapy and virus.

show abstract

Efficacy of convalescent plasma according to blood groups in COVID-19 patients

Cited by 4 publications

References 22 publications

Convalescent plasma – An insight into a novel treatment of covid-19 ICU patients

Convalescent plasma – An insight into a novel treatment of covid-19 ICU patients

A Role of Variance in Interferon Genes to Disease Severity in COVID-19 Patients

Passive Immunity Should and Will Work for COVID-19 for Some Patients

Contact Info

Product

Resources

About